Stock listing

NYSE American:CLDI Calidi Biotherapeutics, Inc. Stock

Home listing (NYSE American) of Calidi Biotherapeutics, Inc.

Follow Calidi Biotherapeutics, Inc. into a list and get an email when it puts out news.

Share price · AMEX:CLDI

$0.478 USD -0.050 (-9.4%)

Close on Nov 20, 2026

Past year -97.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.465 – $0.520 USDNov 20, 2026
Volume
47,777 sharesNov 20, 2026
Market cap
$1.76M USDAt the close on Nov 20, 2026 · price × 3.68M shares outstanding
52-week range
$0.465 – $24.800 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$106,244 USDMedian day 37,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Calidi Biotherapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE American:CLDI · Home$0.478 USD-0.050 (-9.4%)47,777$0.514$0.520$0.465$0.527Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:CLDI · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.478-0.050-9.4%$0.514$0.520$0.46547,777
$0.527-0.032-5.8%$0.556$0.580$0.51618,425
$0.560-0.043-7.1%$0.593$0.593$0.54923,784
$0.602-0.020-3.2%$0.650$0.650$0.60036,516
$0.622-0.033-5.1%$0.656$0.656$0.62227,090
$0.655-0.020-3.0%$0.678$0.701$0.64031,383
$0.675-0.009-1.3%$0.694$0.728$0.67026,662
$0.684-0.049-6.7%$0.733$0.734$0.68315,275
$0.733+0.033+4.7%$0.701$0.765$0.67363,100
$0.700+0.021+3.1%$0.690$0.710$0.67915,720
$0.679-0.051-7.0%$0.711$0.711$0.63032,273
$0.730-0.019-2.5%$0.760$0.792$0.65043,280
$0.749+0.091+13.8%$0.630$0.760$0.63052,484
$0.658-0.030-4.4%$0.698$0.710$0.64933,023
$0.688+0.016+2.4%$0.667$0.688$0.65048,393
$0.672-0.030-4.3%$0.650$0.706$0.65018,203
$0.702+0.042+6.3%$0.700$0.719$0.66427,526
$0.660+0.020+3.1%$0.669$0.700$0.62331,284
$0.640-0.005-0.8%$0.650$0.650$0.63041,419
$0.645-0.005-0.8%$0.650$0.660$0.62937,600
$0.650-0.118-15.4%$0.770$0.770$0.620201,100
$0.768-0.002-0.3%$0.759$0.790$0.73163,700
$0.770-0.013-1.7%$0.750$0.779$0.75026,900
$0.783-0.054-6.5%$0.801$0.831$0.75154,800
$0.837-0.033-3.8%$0.890$0.890$0.79035,100
$0.870-0.004-0.5%$0.870$0.890$0.85723,800
$0.874-0.026-2.9%$0.900$0.920$0.82052,800
$0.900-0.050-5.3%$0.933$0.933$0.87063,800
$0.950-0.080-7.8%$0.998$0.998$0.93752,600
$1.030-0.010-1.0%$1.040$1.050$1.03018,000
$1.040+0.030+3.0%$1.020$1.041$1.00018,200
$1.010-0.010-1.0%$1.020$1.030$0.98651,500
$1.020-0.030-2.9%$1.060$1.070$1.00071,700
$1.050-0.030-2.8%$1.080$1.120$1.00022,000
$1.0800.0000.0%$1.090$1.090$1.05038,600
$1.080+0.010+0.9%$1.065$1.080$1.05014,900
$1.070-0.010-0.9%$1.080$1.095$1.05048,900
$1.080+0.010+0.9%$1.075$1.080$1.03043,200
$1.070-0.060-5.3%$1.100$1.130$1.050154,500
$1.130-0.070-5.8%$1.200$1.290$1.130128,600
$1.200+0.110+10.1%$1.150$1.250$1.100587,800
$1.090-0.020-1.8%$1.100$1.150$1.0502,882,800
$1.110-0.002-0.2%$1.111$1.150$1.11037,100
$1.112+0.012+1.1%$1.110$1.163$1.10033,400
$1.100-0.170-13.4%$1.280$1.280$1.10030,600
$1.270+0.100+8.5%$1.150$1.290$1.050189,000
$1.1700.0000.0%$1.220$1.230$1.16032,400
$1.170-0.050-4.1%$1.210$1.220$1.17033,900
$1.220-0.020-1.6%$1.270$1.270$1.21017,500
$1.240-0.070-5.3%$1.240$1.280$1.22070,600
$1.310-0.050-3.7%$1.310$1.340$1.30032,400
$1.360+0.010+0.7%$1.330$1.370$1.30145,300
$1.350-0.035-2.5%$1.380$1.400$1.25030,000
$1.385+0.035+2.6%$1.380$1.400$1.35019,000
$1.350+0.010+0.7%$1.330$1.380$1.32023,600
$1.340+0.010+0.8%$1.332$1.410$1.33030,100
$1.330-0.010-0.7%$1.330$1.360$1.28048,500
$1.340+0.020+1.5%$1.320$1.380$1.31035,800
$1.320+0.020+1.5%$1.320$1.370$1.28051,800
$1.300-0.050-3.7%$1.330$1.420$1.260129,400
$1.350+0.040+3.1%$1.310$1.370$1.31038,800
$1.310-0.070-5.1%$1.350$1.405$1.31048,200
$1.380+0.040+3.0%$1.340$1.380$1.26062,200
$1.3400.0000.0%$1.350$1.410$1.31058,100
$1.340-0.040-2.9%$1.350$1.390$1.27079,600

Splits

3 splits since 2024 · AMEX:CLDI · every price before a split is adjusted for it

DayRatioWhat
1-for-16Consolidation
1-for-12Consolidation
1-for-10Consolidation
Ticker
NYSE American:CLDI
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NYSE American
Currency
USD

What changed lately

Latest news

All Calidi Biotherapeutics, Inc. news

Calidi Biotherapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
31 in the last 12 months · 56 in all · newest Nov 13, 2026 · oldest 2024
Decks
20 decks · latest April 2026

Where Calidi Biotherapeutics, Inc. is listed

ListingExchangeCountryCurrency
NYSE American:CLDI · Home listing · This pageNYSE AmericanUnited StatesUSD
BOATS:CLDIBOATSUnited StatesUSD

Cash and shares

Sep 30, 2025 · Calidi Biotherapeutics — Investor Presentation (October 2025)

Shares outstanding
7,056,312
Fully diluted
12,339,462

The slide these figures come from

Valuation

Price/book 1.1× against a median of 0.3×: 7th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$2.19M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.1×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.86

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Calidi Biotherapeutics, Inc. · AMEX:CLDIUS$1.76M−US$2.19Mn/an/an/a1.1×n/a0.0×1.86
CASI Pharmaceuticals, Inc. · OTC:CASIFUS$2.06MUS$38.79Mn/a1.9×n/an/a−218.6%n/a-0.07
Vectus Biosystems Limited · ASX:VBSUS$2.02MUS$50,9461.9×n/an/a1.3×n/a0.2×n/a
Decoy Therapeutics Inc. · NASDAQ:DCOYUS$1.98M−US$6.19Mn/a−11.6×n/a0.4×n/a0.0×1.28
Genprex, Inc. · NASDAQ:GNPXUS$1.94M−US$13.41Mn/an/an/a0.1×n/a0.0×1.08
Propanc Biopharma, Inc. · NASDAQ:PPCBUS$1.84MUS$1.62Mn/an/an/a0.3×n/a0.0×1.39
Argent Biopharma Ltd · ASX:RGTUS$1.79MUS$8.05Mn/a75.4×n/an/an/an/an/a
Kala Bio, Inc. · NASDAQ:KALAUS$1.74M−US$5.49Mn/an/an/a0.2×n/a0.0×2.76
SOHM, Inc. · OTC:SHMNUS$1.74MUS$4.99Mn/a5.5×n/a0.5×−28.1%0.9×-0.10
PRF Technologies Ltd. · NASDAQ:PRFXUS$1.66M−US$9.82Mn/a−249×n/a0.1×n/a0.0×1.93
Jupiter Neurosciences, Inc. · NASDAQ:JUNSUS$1.63MUS$1.33Mn/a16.9×n/an/an/an/a1.88
Median of the othersUS$1.82MUS$689,3481.9×3.7×0.3×−123.3%0.0×1.34

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
120.00 USD · Analysts' mean
EPS, year to Dec 2025
-7.44 · 1 analyst

Team and board

Officers

OfficerRole
Eric PomaChief Executive Officer and Director
Andrew JacksonChief Financial Officer
Antonio F. SantidrianChief Scientific Officer and Head of Technical Operations
Guy Travis CliftonChief Medical Officer

Board

DirectorRole
James A. SchoeneckChairman of the Board
Alan StewartBoard Member
Corsee SandersBoard Member
Eric PomaChief Executive Officer and Director
George E. PeoplesBoard Member
Scott LeftwichVice-Chairman of the Board

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026−8.1%
Q2 2026Aug 13, 2026−2.5%
Q3 2025Nov 13, 2025 · After close−1.3%
Q2 2025Aug 8, 2025 · After close+0.6%
Q1 2025May 14, 2025 · After close+3.8%
Q4 2024Mar 31, 2025−14.3%
Q3 2024Nov 12, 2024 · After close+60.2%
Q2 2024Aug 13, 2024 · After close−3.0%
Q1 2024May 14, 2024 · After close+3.5%
Q4 2023Mar 15, 2024 · After close−5.8%
All 19 quarters
QuarterResultsShare move
Q3 2023Nov 14, 2023 · After close+4.5%
Q2 2023Aug 30, 2023+14.5%
Q4 2022Mar 31, 2023+0.2%
Q3 2022Nov 14, 20220.0%
Q2 2022Aug 10, 20220.0%
Q1 2022May 11, 2022−0.1%
Q4 2021Mar 31, 2022+0.4%
Q3 2021Nov 12, 2021+0.5%
Quarter to Jun 30, 2021Sep 13, 2021

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (April 2026)Investor deck13 slidesApril 2026
Investor Presentation (February 2026)Investor deck23 slidesFebruary 2026
Investor Presentation (October 2025)Investor deck22 slidesOct 24, 2025
Investor Presentation (October 2025)Investor deck22 slidesOct 22, 2025
Investor Presentation (August 2025)Investor deck16 slidesAugust 2025
Shareholder Meeting (July 2025)Shareholder meeting14 slidesJuly 2025
Investor Presentation (March 2025)Investor deck27 slidesMarch 2025
Investor Presentation (January 2025)Investor deck31 slidesJan 10, 2025
Investor Presentation (October 2024)Investor deck28 slidesOct 18, 2024
Corporate Update (September 2024)Corporate update27 slidesSep 12, 2024
All 20 decks
DeckKindSlidesDate
Investor Presentation (August 2024)Investor deck23 slidesAug 22, 2024
Investor Presentation (April 2024)Investor deck34 slidesApr 15, 2024
Investor Presentation (April 2024)Investor deck32 slidesApril 2024
Biocom Global Life Science Partnering & Investor Conference 2024Conference18 slidesFeb 28, 2024
Investor Presentation (January 2024)Investor deck33 slidesJanuary 2024
Investor Presentation (December 2023)Investor deck17 slidesDec 19, 2023
First Light Acquisition Group — SPAC Merger (August 2023)SPAC merger67 slidesAug 16, 2023
SPAC Merger (February 2023)SPAC merger25 slidesFeb 10, 2023
SPAC Merger (January 2023)SPAC merger25 slidesJan 9, 2023
SPAC Merger (February 2022)SPAC merger36 slidesFeb 2, 2022

Open Decks

Financings

RaiseDate
Registered direct offering of shares of common stock
Announced: about US$1.2M · US$1.17 a share
Use of proceeds: Working capital and general corporate purposes
Sep 17, 2026
Public offering of units of common stock or pre-funded warrants with common warrants
Announced: Ladenburg Thalmann & Co. Inc.
Dealers: Ladenburg Thalmann & Co. Inc. (lead)
Use of proceeds: Working capital and general corporate purposes
Mar 5, 2026
Public offering of common stock units and pre-funded warrant units
Closed: US$6.9M raised · US$2 a unit · Warrants at US$2 for 60 months · Ladenburg Thalmann & Co. Inc. +1
Dealers: Ladenburg Thalmann & Co. Inc. (lead), Laidlaw & Company (U.K.) Ltd.
Insiders: Management and board members participated
Aug 21, 2025
Warrant exercise of warrant inducement offering
Closed: US$4.6M raised · US$0.7 a share · ½ warrant at US$0.7 for 66 months · Ladenburg Thalmann & Co, Inc.
Dealers: Ladenburg Thalmann & Co, Inc. (lead)
Use of proceeds: Advance clinical and pre-clinical programs, continuing operating expenses and working capital
Aug 8, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as First Light Acquisition Group, Inc., a blank check company (SPAC). Priced at US$10.00 a unit on Sep 9, 2021.

Price
US$10.00 a unit
Units offered
20,000,000 units
Offering size
US$200 million
Underwriters' option
Up to 3,000,000 more units
Underwriter
Guggenheim Securities
Units delivered
On or about Sep 14, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceMay 17, 2021
Filed publiclyAug 24, 2021
Amended onceSep 7, 2021
Shares registered with an exchangeSep 9, 2021
Declared effective by the SECSep 9, 2021
Final prospectus, with the priceSep 13, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Sep 13, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue00045.0K449.0K0
Cost of revenue1.65M1.53M1.26M274.0K94.0K0
Gross profit-1.65M-1.53M-1.26M-229.0K355.0K0
Research and development9.74M8.88M13.0M7.26M4.67M3.18M
Selling, general and administrative10.5M12.9M16.0M15.9M6.16M3.59M
Operating income-20.2M-21.8M-29.0M-23.1M-10.5M-6.77M
Depreciation and amortization1.65M1.53M392.0K260.0K153.0K117.0K
EBITDA-18.6M-20.2M-28.6M-22.9M-10.3M-6.66M
Interest expense100.0K700.0K1.10M200.0K614.0K163.0K
Income before tax-20.0M-22.2M-29.2M-25.4M3.40M-7.93M
Income tax15.0K14.0K16.0K11.0K11.0K4.00K
Net income-19.9M-22.1M-29.2M-25.4M-10.9M-7.94M
Earnings per share, basic-5.95-35.70-17.332.99-733.07-42.61
Earnings per share, diluted-5.95-35.70-17.332.99

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents5.60M9.60M1.95M372.0K2.14M420.0K
Receivables1.36M870
Current assets6.26M10.2M4.30M786.0K2.74M513.0K
Property, plant and equipment781.0K869.0K1.27M1.27M585.0K723.0K
Total assets8.86M14.2M10.0M2.60M3.39M1.85M
Accounts payable595.0K2.07M2.88M51.1K624.0K822.0K
Current liabilities3.94M9.50M10.2M43.0M26.0M8.89M
Long-term debt600.0K600.0K2.06M6.37M
Total debt600.0K600.0K2.06M5.42M5.18M11.7M
Total liabilities5.10M12.2M18.3M43.4M26.0M24.3M
Shareholders' equity3.76M1.53M-8.23M-50.4M-22.6M-22.5M
Shares outstanding451.1K1.73M3.55M8.58M14.9K186.3K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-21.3M-19.7M-27.0M-13.2M-7.77M-4.83M
Capital spending-120.0K-16.0K-585.0K-428.0K-206.0K-351.0K
Free cash flow-21.4M-19.7M-27.6M-13.6M-7.98M-5.18M
Cash from investing-170.0K-16.0K-478.0K-494.0K-215.0K-388.0K
Cash from financing17.5M27.4M29.0M12.1M9.81M4.70M
Dividends paid-5.67M-1.67M
Share buybacks0-175.0K
Change in cash-3.99M7.64M1.58M-968.8K1.82M-514.0K

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 13, 2026ResultsSEC
8-K · Current reportSep 25, 2026Current reportSEC
8-K · Current reportSep 22, 2026Material contractSEC
424B5 · ProspectusSep 17, 2026Offer documentSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipAug 19, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
8-K · Current reportJul 31, 2026Current reportSEC
8-K · Current reportJul 16, 2026Material contractSEC
3 · Initial statement of ownershipJun 29, 2026Insider tradeSEC
8-K · Current reportJun 23, 2026Management or board changeSEC
8-K · Current reportJun 18, 2026Meeting outcomeSEC
DEFA14A · Additional proxy materialJun 5, 2026Meeting noticeSEC
8-K · Current reportMay 29, 2026Material contractSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
8-K · Current reportMay 8, 2026Material contractSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 17, 2026Meeting noticeSEC
8-K · Current reportApr 2, 2026Management or board changeSEC
SCHEDULE 13D · Big-stake noticeMar 31, 2026Big-stake noticeSEC
10-K · Annual reportMar 27, 2026Annual reportSEC
8-K · Current reportMar 27, 2026ResultsSEC
8-K · Current reportMar 11, 2026Material contractSEC
SCHEDULE 13D · Big-stake noticeMar 9, 2026Big-stake noticeSEC
424B5 · ProspectusMar 6, 2026Offer documentSEC
S-3MEFMar 5, 2026Other filingsSEC
424B5 · ProspectusMar 5, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2026Big-stake noticeSEC
8-K · Current reportFeb 9, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 4, 2026Big-stake noticeSEC
8-K · Current reportJan 28, 2026ResultsSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
8-K · Current reportNov 10, 2025Current reportSEC
8-K · Current reportOct 31, 2025Acquisition or disposalSEC
8-K · Current reportOct 24, 2025Current reportSEC
8-K · Current reportSep 19, 2025Material contractSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
8-K · Current reportAug 29, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 27, 2025Big-stake noticeSEC
3 · Initial statement of ownershipAug 27, 2025Insider tradeSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
8-K · Current reportAug 22, 2025Material contractSEC
424B4 · ProspectusAug 21, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 21, 2025Other filingsSEC
CORRESP · Letter to the SECAug 19, 2025Other filingsSEC
CORRESP · Letter to the SECAug 19, 2025Other filingsSEC
S-1 · Registration statementAug 15, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
8-K · Current reportAug 14, 2025Material contractSEC
10-Q · Quarterly reportAug 8, 2025Quarterly reportSEC
8-K · Current reportAug 8, 2025ResultsSEC
8-K · Current reportAug 7, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveJul 28, 2025Other filingsSEC
8-K · Current reportJul 25, 2025Management or board changeSEC
CORRESP · Letter to the SECJul 24, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 22, 2025Other filingsSEC
S-3 · Registration statementJul 18, 2025Offer documentSEC
4 · Change in ownershipJul 15, 2025Insider tradeSEC
4 · Change in ownershipJul 15, 2025Insider tradeSEC
4 · Change in ownershipJul 15, 2025Insider tradeSEC
4 · Change in ownershipJul 15, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveJul 14, 2025Other filingsSEC
8-K · Current reportJul 11, 2025Meeting outcomeSEC
CORRESP · Letter to the SECJul 10, 2025Other filingsSEC
424B3 · ProspectusJul 10, 2025Offer documentSEC
424B3 · ProspectusJul 10, 2025Offer documentSEC
8-K · Current reportJul 10, 2025Material contractSEC
UPLOAD · Letter from the SECJul 8, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 8, 2025Other filingsSEC
S-1 · Registration statementJul 3, 2025Offer documentSEC
DRS · Draft registration statementJul 2, 2025Offer documentSEC
DEFA14A · Additional proxy materialMay 23, 2025Meeting noticeSEC
DEF 14A · Proxy statementMay 23, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
8-K · Current reportMay 14, 2025ResultsSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
PRE 14A · Preliminary proxy statementMay 12, 2025Meeting noticeSEC
8-K · Current reportMay 2, 2025Current reportSEC
4 · Change in ownershipApr 25, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 25, 2025Insider tradeSEC
8-K · Current reportApr 23, 2025Material contractSEC
8-K · Current reportApr 9, 2025Current reportSEC
8-K · Current reportApr 1, 2025Material contractSEC
8-K · Current reportMar 31, 2025ResultsSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
424B5 · ProspectusMar 31, 2025Offer documentSEC
8-K · Current reportMar 10, 2025Current reportSEC
8-K/A · Current report, amendedFeb 10, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveFeb 10, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 6, 2025Other filingsSEC
424B5 · ProspectusFeb 5, 2025Offer documentSEC
8-K · Current reportFeb 4, 2025Current reportSEC
8-K · Current reportJan 28, 2025ResultsSEC
UPLOAD · Letter from the SECJan 15, 2025Other filingsSEC
S-3 · Registration statementJan 10, 2025Offer documentSEC
8-K · Current reportJan 10, 2025Current reportSEC
8-K · Current reportJan 10, 2025Material contractSEC
424B5 · ProspectusJan 10, 2025Offer documentSEC
424B5 · ProspectusJan 8, 2025Offer documentSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveDec 30, 2024Other filingsSEC
CORRESP · Letter to the SECDec 26, 2024Other filingsSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
UPLOAD · Letter from the SECDec 17, 2024Other filingsSEC
S-1 · Registration statementDec 12, 2024Offer documentSEC
424B5 · ProspectusNov 29, 2024Offer documentSEC
8-K · Current reportNov 18, 2024Current reportSEC
8-K · Current reportNov 15, 2024Material contractSEC
424B5 · ProspectusNov 15, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
424B5 · ProspectusNov 14, 2024Offer documentSEC
8-K · Current reportNov 12, 2024ResultsSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
25-NSEOct 28, 2024Other filingsSEC
8-K · Current reportOct 24, 2024Material contractSEC
424B5 · ProspectusOct 24, 2024Offer documentSEC
424B5 · ProspectusOct 23, 2024Offer documentSEC
8-K · Current reportOct 18, 2024Current reportSEC
8-K · Current reportOct 18, 2024Current reportSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
424B5 · ProspectusOct 11, 2024Offer documentSEC
8-K · Current reportOct 11, 2024Material contractSEC
EFFECT · Notice that a registration is effectiveOct 11, 2024Other filingsSEC
CORRESP · Letter to the SECOct 8, 2024Other filingsSEC
S-3/A · Registration statement, amendedOct 7, 2024Offer documentSEC
UPLOAD · Letter from the SECOct 7, 2024Other filingsSEC
S-3 · Registration statementOct 1, 2024Offer documentSEC
S-8 · Registration statement for employee plansOct 1, 2024Offer documentSEC
4 · Change in ownershipSep 30, 2024Insider tradeSEC
8-K · Current reportSep 30, 2024Current reportSEC
8-K · Current reportSep 23, 2024Meeting outcomeSEC
8-K · Current reportSep 12, 2024Current reportSEC
SC 13G · Big-stake noticeSep 11, 2024Big-stake noticeSEC
8-K · Current reportAug 22, 2024Current reportSEC
8-K · Current reportAug 20, 2024Management or board changeSEC
DEF 14A · Proxy statementAug 19, 2024Meeting noticeSEC
8-K · Current reportAug 13, 2024ResultsSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportJul 29, 2024Material contractSEC
8-K · Current reportJul 15, 2024Current reportSEC
4 · Change in ownershipJul 11, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 11, 2024Insider tradeSEC
8-K · Current reportJul 8, 2024Material contractSEC
8-K · Current reportJul 5, 2024Current reportSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
8-K · Current reportJun 26, 2024Management or board changeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
4 · Change in ownershipJun 20, 2024Insider tradeSEC
8-K · Current reportJun 11, 2024Meeting outcomeSEC
DJun 5, 2024Other filingsSEC
4 · Change in ownershipJun 5, 2024Insider tradeSEC
424B3 · ProspectusJun 4, 2024Offer documentSEC
8-K · Current reportJun 4, 2024Material contractSEC
8-K · Current reportMay 31, 2024Material contractSEC
8-K · Current reportMay 17, 2024Management or board changeSEC
424B3 · ProspectusMay 16, 2024Offer documentSEC
8-K · Current reportMay 16, 2024Management or board changeSEC
8-K · Current reportMay 14, 2024ResultsSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
DEF 14A · Proxy statementMay 9, 2024Meeting noticeSEC
SCHEDULE 13D · Big-stake noticeMay 1, 2024Big-stake noticeSEC
PRE 14A · Preliminary proxy statementApr 29, 2024Meeting noticeSEC
4 · Change in ownershipApr 22, 2024Insider tradeSEC
8-K · Current reportApr 19, 2024Current reportSEC
8-K · Current reportApr 19, 2024Material contractSEC
8-K · Current reportApr 18, 2024Material contractSEC
424B4 · ProspectusApr 17, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 17, 2024Other filingsSEC
CORRESP · Letter to the SECApr 15, 2024Other filingsSEC
CORRESP · Letter to the SECApr 15, 2024Other filingsSEC

This page holds 200 of 408 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Calidi Biotherapeutics, Inc.’s releases · as of Sep 17, 2026

Common shares
3,676,474
Fully diluted
3,676,474

Fully diluted

LineShares
Common shares3,676,474

Warrants and options

Lot
Warrants · US$2.00 · expire about Aug 2030
Warrants · US$0.70 · expire about Jan 2031

Share count over time

CountShares
Nov 22, 20263,676,474
Jul 20, 2026

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Farther Finance Advisors, LLC6250.02%US$669Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund49,7761.4%US$9,209May 31, 2026
Vanguard Extended Market Index Fund25,5090.74%US$4,337Jun 30, 2026
Fidelity Total Market Index Fund5,1500.15%US$953May 31, 2026
Fidelity Series Total Market Index Fund4,6440.13%US$859May 31, 2026

Big stakes

StakeStakeSharesDateFiling
Armistice Capital, LLC9.99%1.11MMar 31, 2026Schedule 13G
Gavrilov Ognian Anguelov0.30%20,000Mar 31, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Corazon D Sanders
Other companies: BeOne Medicines Ltd. Class A (Director · Since at least May 22, 2026); Legend Biotech Corp. (Director · Since at least Mar 18, 2026); Ultragenyx Pharmaceutical Inc. (Director · Since at least Jun 29, 2021); Molecular Templates Inc (Director · Dec 19, 2019 – Sep 27, 2024 · Past)
Director · Since at least Jun 17, 2026
George Ng
Other companies: TuHURA Biosciences, Inc. (Director · Since at least Oct 18, 2024); Processa Pharmaceuticals, Inc. (Chief Executive Officer, Director · Since at least Aug 8, 2023)
Director · Sep 12, 2023 – Sep 12, 2023 · Past
James A. Schoeneck
Other companies: Connect Biopharma Holdings Limited (Board Director · Since at least Jul 22, 2025); Kyntra Bio, Inc. (Director · Since at least Jun 5, 2024)
Director · Since at least Dec 21, 2023
Michael C Ruettgers
Other companies: Gigamon Inc (Director · Jun 11, 2013 – Dec 27, 2017 · Past); Raytheon Company (Director · May 28, 2009 – May 26, 2016 · Past)
Director · Sep 9, 2021 – Sep 9, 2021 · Past
Tony T Kalajian
Other companies: Beyond Meat, Inc. (Chief Accounting Officer · Since at least Jan 12, 2026); Insight Molecular Diagnostics Inc. (Sr.VP/Chief Accounting Officer · Aug 9, 2019 – Aug 3, 2020 · Past)
Chief Acctg Officer, Int. CFO · Sep 12, 2023 – Sep 12, 2023 · Past
Alan Stewart
Other companies: SoundThinking, Inc. (Chief Financial Officer · Since at least Nov 11, 2022)
Director · Since at least Oct 10, 2023
Eric Poma
Other companies: Molecular Templates Inc (See remarks, Director · Oct 9, 2017 – Jan 23, 2024 · Past)
Chief Executive Officer · Since at least Apr 22, 2025
William John Weber
Other companies: The KeyW Holding Corporation (President/CEO, Director · May 9, 2019 – Jun 11, 2019 · Past)
Chief Executive Officer, Director · Sep 9, 2021 – Sep 9, 2021 · Past
Amish PatelVP of Technical Operations · Sep 12, 2023 – Sep 12, 2023 · Past
Andrew JacksonChief Financial Officer · Since at least Apr 22, 2025
All 20 people
PersonSeat
Antonio F. SantidrianChief Scientific Officer and Head of Technical Operations · Since at least May 26, 2026
Boris Radoslavov MinevInterim Chief Medical Officer · Sep 12, 2023 – Jun 17, 2024 · Past
Corsee SandersBoard Member · Since at least Jun 23, 2026
David LaPreDirector · Jan 1, 2024 – Jan 1, 2024 · Past
George E. PeoplesBoard Member · Since at least Nov 4, 2026
Guy Travis CliftonChief Medical Officer · Since at least Jul 29, 2025
Scott LeftwichVice-Chairman of the Board · Since at least Sep 12, 2023
Stephen ThesingChief Business Officer · Sep 12, 2023 – Sep 12, 2023 · Past
Thomas A VecchiollaDirector · Dec 21, 2023 – Dec 21, 2023 · Past
Wendy Pizarro CampbellChief Admin. and Legal Officer · Sep 12, 2023 – Jun 17, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Calidi Biotherapeutics, Inc.